Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CLLS
- Price
- 4.37
- Stock movement up
- +0.26 (6.33%)
- Company name
- Cellectis SA
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 316.06M
- Ent value
- 506.39M
- Price/Sales
- 4.20
- Price/Book
- 3.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -31.61%
- 1 year return (CAGR)
- 189.40%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CLLS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.20 |
| Price to Book | 3.15 |
| EV to Sales | 6.73 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 72.33M |
| EPS (TTM) | -0.35 |
| FCF per share (TTM) | -0.33 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 75.27M |
| Gross profit (TTM) | 65.96M |
| Operating income (TTM) | -26.41M |
| Net income (TTM) | -35.35M |
| EPS (TTM) | -0.35 |
| EPS (1y forward) | -0.62 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.63% |
| Operating margin (TTM) | -35.08% |
| Profit margin (TTM) | -46.97% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 52.24M |
| Net receivables | 8.06M |
| Total current assets | 221.19M |
| Goodwill | 0.00 |
| Intangible assets | 845.00K |
| Property, plant and equipment | 177.56M |
| Total assets | 343.05M |
| Accounts payable | 16.09M |
| Short/Current long term debt | 37.58M |
| Total current liabilities | 148.58M |
| Total liabilities | 242.57M |
| Shareholder's equity | 100.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -29.09M |
| Capital expenditures (TTM) | 3.63M |
| Free cash flow (TTM) | -32.71M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -35.18% |
| Return on Assets | -10.31% |
| Return on Invested Capital | -22.30% |
| Cash Return on Invested Capital | -20.63% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.13 |
| Daily high | 4.39 |
| Daily low | 4.13 |
| Daily Volume | 44K |
| All-time high | 47.66 |
| 1y analyst estimate | 7.20 |
| Beta | 3.04 |
| EPS (TTM) | -0.35 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 Mar 2026 |
Downside potential
Loading...
Downside potential data
| CLLS | S&P500 | |
| Current price drop from All-time high | -90.83% | -0.89% |
| Highest price drop | -97.59% | -19.00% |
| Date of highest drop | 4 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -94.92% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
316.06M
Marketcap category
Small-cap
Description
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Employees
216
Website
Investor relations
SEC filings
CEO
André Choulika
Country
USA
City
Paris
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page